Latest news with #EksoBionics
Yahoo
12-06-2025
- Business
- Yahoo
Exoskeleton Market Research and Global Forecast Report 2025-2030: Powered Exoskeletons Lead Growth with Robust Investment Activities, Industrial Adoption Amplifies Expansion
The exoskeleton market is projected to grow from USD 0.56 billion in 2025 to USD 2.03 billion by 2030, with a CAGR of 29.4%. Exoskeletons enhance mobility for those with physical impairments and reduce industrial workers' strain, boosting demand in healthcare and manufacturing. The rise in the elderly population and home rehabilitation heightens this need. Technological advancements, including AI and improved materials, are enhancing exoskeleton functionality and availability. Significant investments, such as those in German Bionic and Verve Motion, highlight the industry's growth potential. Key players include Ekso Bionics, Ottobock, and CYBERDYNE Inc. Exoskeleton Market Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Exoskeleton Market by Component (Sensors, Actuators, Power Systems, Controllers, Software), Functionality (Assistive, Rehabilitative, Augmentative, Preventive), Type (Powered, Passive, Hybrid), Body Part (Lower, Upper, Full Body) - Global Forecast to 2030" has been added to offering. The exoskeleton market is anticipated to grow significantly, from USD 0.56 billion in 2025 to USD 2.03 billion by 2030, with a robust CAGR of 29.4% This surge is driven by its expanding integration into healthcare and manufacturing sectors, aiding mobility for physically impaired individuals while reducing industrial workers' physical strain. An aging population and increased home care rehabilitation further propel the demand. The evolution of technology, including AI, sensors, and lightweight materials, enhances the affordability, accessibility, and performance of exoskeletons. Investment from both public and private sectors will continue to bolster product innovation and market growth. Key players in the market include Ekso Bionics (US), Ottobock (Germany), DIH Medical (Switzerland), Comau (Italy), Myomo Inc. (US), CYBERDYNE Inc. (Japan), Lifeward Ltd. (Israel), Hyundai Motor Group Robotics LAB. (South Korea), B-Temia (Canada), Rex Bionics Ltd. (New Zealand), among Exoskeletons Gaining Momentum The powered exoskeleton sector is witnessing robust growth, exemplified by the strategic investments and increased investor confidence in its commercial viability. German Bionic, an innovator in electrically powered exoskeletons, secured over USD 16.3 million in an extended Series A funding round in December 2023. This investment aims to enhance collaboration with Mubea and scale production for better market deployment. Additionally, Verve Motion, a Cambridge-based startup specializing in robotic exosuits, raised USD 20 million in a Series B funding round to further its market reach. These developments highlight the strategic investment in powered exoskeleton technology, poised to revolutionize industrial automation, injury prevention, and workforce Sector's Rapid Adoption The industrial sector is increasingly adopting exoskeletons to boost worker safety, mitigate fatigue, and enhance productivity. They are essential in industries such as manufacturing, logistics, and assembly lines, where repetitive tasks are prevalent. Exoskeletons help mitigate musculoskeletal injuries by supporting the lower back, shoulders, and legs, thereby reducing the occupational health costs and improving Leading Europe Germany leads the European exoskeleton market with strong industrial demand and innovation in healthcare, supported by significant private investments. Its robust manufacturing and logistics sectors actively integrate exoskeletons to enhance workforce efficiency and reduce musculoskeletal injuries. Companies like German Bionic are at the forefront, raising over USD 16.3 million to advance their product offerings, with models like Apogee and Apogee+ significantly impacting logistics, retail, and healthcare sectors with their ergonomic Insights Include: Analysis of market drivers, restraints, opportunities, and challenges. Insights into upcoming technologies, R&D activities, and product launches. Comprehensive information on lucrative markets. In-depth competitive assessments and strategic analysis of leading players. Key Attributes: Report Attribute Details No. of Pages 255 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $0.56 Billion Forecasted Market Value (USD) by 2030 $2.03 Billion Compound Annual Growth Rate 29.4% Regions Covered Global Market Dynamics Drivers Rising Demand for Robotic Rehabilitation Solutions From Healthcare Sector Increased Adoption in Industrial and Manufacturing Sectors Increased FDA Approvals for Medical Exoskeletons Challenges High Cost of Ownership Comfort and Movement Interference for Workers Power Supply Limitations and Operational Downtime Opportunities Integration of Exoskeletons With AI and IoT Technologies Increasing Adoption of Exoskeletons in Military and Defense Sectors Case Studies Enhancing Worker Ergonomics and Productivity At John Deere With Comau's Mate-Xt Wearable Exoskeleton Enhancing Logistics Operations and Worker Well-Being At Fiege Group With German Bionic AI-Powered Exoskeleton Technology Enhancing Worker Safety and Productivity in Tunnel Construction At Granite Construction With Levitate Technologies Exoskeletons Reducing Physical Strain in Truck Maintenance At Man Truck & Bus With Help of Suitx Technology by Ottobock Ford Motor Company Enhances Worker Safety and Reduces Injuries With Ekso Bionics Eksovest Company Profiles Ekso Bionics Ottobock DIH Medical Comau Myomo Inc. Cyberdyne Inc. Lifeward Ltd. Hyundai Motor Group Robotics Lab. B-Temia Rex Bionics Ltd. Able Human Motion Laevo Exoskeletons German Bionic Systems GmbH Levitate Technologies, Inc. Fourier Trexo Robotics Wandercraft Agade Europe Technologies Archelis Inc. P&S Mechanics Co., Ltd. Rb3D Japet Medical Devices Proteso S.R.L. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Exoskeleton Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
12-06-2025
- Business
- Yahoo
Exoskeleton Market Research and Global Forecast Report 2025-2030: Powered Exoskeletons Lead Growth with Robust Investment Activities, Industrial Adoption Amplifies Expansion
The exoskeleton market is projected to grow from USD 0.56 billion in 2025 to USD 2.03 billion by 2030, with a CAGR of 29.4%. Exoskeletons enhance mobility for those with physical impairments and reduce industrial workers' strain, boosting demand in healthcare and manufacturing. The rise in the elderly population and home rehabilitation heightens this need. Technological advancements, including AI and improved materials, are enhancing exoskeleton functionality and availability. Significant investments, such as those in German Bionic and Verve Motion, highlight the industry's growth potential. Key players include Ekso Bionics, Ottobock, and CYBERDYNE Inc. Exoskeleton Market Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Exoskeleton Market by Component (Sensors, Actuators, Power Systems, Controllers, Software), Functionality (Assistive, Rehabilitative, Augmentative, Preventive), Type (Powered, Passive, Hybrid), Body Part (Lower, Upper, Full Body) - Global Forecast to 2030" has been added to offering. The exoskeleton market is anticipated to grow significantly, from USD 0.56 billion in 2025 to USD 2.03 billion by 2030, with a robust CAGR of 29.4% This surge is driven by its expanding integration into healthcare and manufacturing sectors, aiding mobility for physically impaired individuals while reducing industrial workers' physical strain. An aging population and increased home care rehabilitation further propel the demand. The evolution of technology, including AI, sensors, and lightweight materials, enhances the affordability, accessibility, and performance of exoskeletons. Investment from both public and private sectors will continue to bolster product innovation and market growth. Key players in the market include Ekso Bionics (US), Ottobock (Germany), DIH Medical (Switzerland), Comau (Italy), Myomo Inc. (US), CYBERDYNE Inc. (Japan), Lifeward Ltd. (Israel), Hyundai Motor Group Robotics LAB. (South Korea), B-Temia (Canada), Rex Bionics Ltd. (New Zealand), among Exoskeletons Gaining Momentum The powered exoskeleton sector is witnessing robust growth, exemplified by the strategic investments and increased investor confidence in its commercial viability. German Bionic, an innovator in electrically powered exoskeletons, secured over USD 16.3 million in an extended Series A funding round in December 2023. This investment aims to enhance collaboration with Mubea and scale production for better market deployment. Additionally, Verve Motion, a Cambridge-based startup specializing in robotic exosuits, raised USD 20 million in a Series B funding round to further its market reach. These developments highlight the strategic investment in powered exoskeleton technology, poised to revolutionize industrial automation, injury prevention, and workforce Sector's Rapid Adoption The industrial sector is increasingly adopting exoskeletons to boost worker safety, mitigate fatigue, and enhance productivity. They are essential in industries such as manufacturing, logistics, and assembly lines, where repetitive tasks are prevalent. Exoskeletons help mitigate musculoskeletal injuries by supporting the lower back, shoulders, and legs, thereby reducing the occupational health costs and improving Leading Europe Germany leads the European exoskeleton market with strong industrial demand and innovation in healthcare, supported by significant private investments. Its robust manufacturing and logistics sectors actively integrate exoskeletons to enhance workforce efficiency and reduce musculoskeletal injuries. Companies like German Bionic are at the forefront, raising over USD 16.3 million to advance their product offerings, with models like Apogee and Apogee+ significantly impacting logistics, retail, and healthcare sectors with their ergonomic Insights Include: Analysis of market drivers, restraints, opportunities, and challenges. Insights into upcoming technologies, R&D activities, and product launches. Comprehensive information on lucrative markets. In-depth competitive assessments and strategic analysis of leading players. Key Attributes: Report Attribute Details No. of Pages 255 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $0.56 Billion Forecasted Market Value (USD) by 2030 $2.03 Billion Compound Annual Growth Rate 29.4% Regions Covered Global Market Dynamics Drivers Rising Demand for Robotic Rehabilitation Solutions From Healthcare Sector Increased Adoption in Industrial and Manufacturing Sectors Increased FDA Approvals for Medical Exoskeletons Challenges High Cost of Ownership Comfort and Movement Interference for Workers Power Supply Limitations and Operational Downtime Opportunities Integration of Exoskeletons With AI and IoT Technologies Increasing Adoption of Exoskeletons in Military and Defense Sectors Case Studies Enhancing Worker Ergonomics and Productivity At John Deere With Comau's Mate-Xt Wearable Exoskeleton Enhancing Logistics Operations and Worker Well-Being At Fiege Group With German Bionic AI-Powered Exoskeleton Technology Enhancing Worker Safety and Productivity in Tunnel Construction At Granite Construction With Levitate Technologies Exoskeletons Reducing Physical Strain in Truck Maintenance At Man Truck & Bus With Help of Suitx Technology by Ottobock Ford Motor Company Enhances Worker Safety and Reduces Injuries With Ekso Bionics Eksovest Company Profiles Ekso Bionics Ottobock DIH Medical Comau Myomo Inc. Cyberdyne Inc. Lifeward Ltd. Hyundai Motor Group Robotics Lab. B-Temia Rex Bionics Ltd. Able Human Motion Laevo Exoskeletons German Bionic Systems GmbH Levitate Technologies, Inc. Fourier Trexo Robotics Wandercraft Agade Europe Technologies Archelis Inc. P&S Mechanics Co., Ltd. Rb3D Japet Medical Devices Proteso S.R.L. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Exoskeleton Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Business Insider
31-05-2025
- Business
- Business Insider
Ekso Bionics trading halted, news pending
19:50 EDT Ekso Bionics (EKSO) trading halted, news pending Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Business Insider
20-05-2025
- Business
- Business Insider
Ekso Bionics to effect 1-for-15 reverse stock split
Ekso Bionics announced that it will effect a reverse stock split of shares of its common stock at a ratio of 1-for-15, effective as of May 27at 12:01 a.m. Pacific time. The company's common stock will open for trading on Nasdaq Capital Market on May 27 on a split-adjusted basis under the existing symbol (EKSO). The company's common stock will trade under a new CUSIP number 282644 400 upon the effectiveness of the reverse stock split. Upon the effectiveness of the reverse stock split, the number of shares of the company's outstanding common stock will decrease from approximately 35,289,695 pre-split shares to approximately 2,352,646 post-split shares, with no change in par value per share. The reverse stock split was approved by the company's shareholders at a special meeting held on May 16, 2025, and is primarily intended to raise the per share trading price of the Company's common stock and, in particular, enable the Company to regain compliance with the minimum bid price requirement for maintaining its listing on The Nasdaq Capital Market. To regain compliance, the closing bid price of the company's common stock must be at least $1.00 for a minimum of ten consecutive trading days. Confident Investing Starts Here:
Associated Press
15-05-2025
- Business
- Associated Press
Ekso Bionics Accepted into NVIDIA Connect Program
Company unveils a strategic initiative to build the world's first known foundation model for human motion in physical rehabilitation Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics' proprietary exoskeleton technology platforms SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ('Ekso Bionics' or the 'Company'), an industry leader in exoskeleton technology for medical and industrial use, today announced its acceptance into the NVIDIA Connect program. The Company plans to use the valuable tools and resources provided through this prestigious NVIDIA program to support a new strategic initiative to build a proprietary foundation model for human motion, and to help develop and integrate related new artificial intelligence ('AI') capabilities across its portfolio of Enterprise Health and Personal Health devices. NVIDIA Connect is a selective program that brings together emerging and established technology companies to accelerate product development and increase cost efficiency. Members gain specialized training, priority engineering support, and exclusive access to NVIDIA's advanced development kits, GPU platforms, and global ecosystem, helping facilitate the program members' ability to deliver next-generation solutions in AI and high-performance computing. 'We are privileged to join a select group of medical device innovators in the NVIDIA Connect program,' said Scott Davis, Chief Executive Officer of Ekso Bionics. 'While our advanced exoskeleton technology platforms are already state-of-the-art, in some ways we are only just approaching the starting line as we work to build and leverage what we believe will be the industry's first known foundation model for human motion in physical rehabilitation. We are excited for this journey with NVIDIA Connect and look forward to updating all of our stakeholders as we progress.' About Ekso Bionics® Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Based upon its industry-leading expertise, the Company focuses on improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol 'EKSO.' For more information, visit: Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding the plans, objectives and expectations of management with respect to the Company's industry, growth and strategy, including the Company's plan to build a proprietary model for human motion and the expected benefits of AI capabilities and being a part of the NVIDIA Connect program. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to realize the benefits of the NVIDIA Connect program or successfully complete the building of a proprietary model for human motion, the Company's inability develop and integrate related new AI capabilities across its portfolio, the Company's inability to obtain adequate financing to fund and grow the Company's operations and necessary to develop or enhance the Company's technology, the Company's inability to successfully collaborate with its network of existing neuro-rehabilitation facilities, physicians, and DMEs in seeking CMS reimbursements, the Company's inability to obtain future reimbursements from CMS in a timely manner and at the expected reimbursement levels, the Company's ability to raise funds to operate and grow its business, the Company's inability to obtain insurance coverage beyond CMS, the Company's inability to obtain additional indications of use for its devices, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of the Company's sales and marketing efforts or of partners to market the Company's products effectively, adverse results in future clinical studies of the Company's medical device products, the failure of the Company to obtain or maintain patent protection for the Company's technology, the failure of the Company to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, disruptions in the Company's supply chain, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's most recently filed Annual Report on Form 10-K and its subsequently filed Quarterly Reports on Form 10-Q. To learn more about Ekso Bionics please visit the Company's website at or refer to the Company's X page, formerly Twitter, at @EksoBionics. Any forward-looking statements made in this press release speak only as of the date of this press release. The Company does not undertake to update these forward-looking statements, except as required by law. Contact: Stephen Kilmer Investor Relations Direct: (646) 274-3580 Email: [email protected]
